GH: Guardant Health, Inc. PEG Multiple

Corporate company logo of Guardant Corp (GH)

The PEG momentum indicator on GURU.Markets demonstrates the market valuation of Guardant Health, Inc. (GH), where the current level is 0.00. This trend is based on the integration of tests into clinics and B2B partnerships, which are limited by FDA regulations. Growth depends on Medicare insurance reimbursements and the control of development expenses. Meanwhile, Guardant Health, Inc. (GH) adheres to ESG standards through the safe processing of bio-waste and eco-friendly logistics.

Guardant Health, Inc. - GH Price/Earnings to Growth Multiple (period 07/04/2022 - 11/10/2026)

Analytical breakdowns for Guardant Health, Inc. (GH)

- stock price and consensus target price:
Share Price Guardant Health Inc|GH - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Guardant360|GH - Total Company Value
- balance sheet equity data:
Net Assets per Single Share Guardant Health|GH - Company Net Assets|Market-to-Book Ratio guardanthealth.com|GH - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Guardant Health, Inc.|GH - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient guardanthealth.com|GH - Company Debts|Debts to Net Assets Guardant360|GH - Company Long-Term Debts|Short-Term Indebtedness Guardant Health|Quick Ratio guardanthealth.com
- financial results and valuation multiples details:
GH - Net Profit|Projected Future Earnings Guardant Health, Inc.|GH - Price to Earnings Ratio|Future Price to Earnings Multiple Guardant Corp|GH - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Guardant360|GH - Operating profit EBITDA|Net earnings per share (EPS TTM) Guardant Health|GH - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months guardanthealth.com|GH - Net earnings per share growth this year|Projected earnings per share increase next year Guardant Health, Inc.
Fundamental company analysis:GH, Guardant Health Inc
Core merchandise of Guardant Health

The PEG ratio compares the P/E ratio with earnings growth rates, allowing for the determination of an asset's fair value relative to its expansion: a value below one signals that the business is undervalued. Analyzing the P/E and growth valuation for Guardant Health, Inc. (GH) is critical amid geopolitical barriers in clinical trials, which could slow the scaling of tests and reduce the asset's resilience.

Competing companies

Caris Life Sciences Inc - Growth-Adjusted P/E Ratio|PEG Multiple VCYT (Veracyte Corp)|PEG Multiple Celcuity Therapeutics CELC|GRAL - Price/Earnings to Growth Ratio|MYGN: Price/Earnings to Growth Ratio|CSTL (Castle Biosciences, Inc.) - Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate Burning Rock Biotech Limited (BNR)|Price/Earnings to Growth Ratio VolitionRx Ltd.|Biodesix Corporation (BDSX) - Growth-Adjusted Market Cap to Net Income|PEG Multiple PRPO|Growth-Adjusted Market Cap to Net Income check-cap.com|Price/Earnings to Growth Ratio Mainz Biomed N.V. MYNZ|Growth-Adjusted Market Cap to Net Income OncoCyte Corp (OCX)